Fig 7. LTA1 and dmLT actiation of APCs is not prevented by PKA-specific inhibitors Myr-14-22 or Rp-cAMPS.
THP-1 cells were treated with media alone (untx), 1 μg/ml dmLT or 10 μg/ml LTA1 treatments per 1x106/ml cells (grey bars or histograms) or pre-incubated for 1h with 20 μM H89, 5 or 25 μM Myr-14-22, or 5 or 25 μM Rp-cAMPS prior to treatments (blue, red, and purple lines or bars). Cytometric samples and experiments performed in triplicate, cytokine analyses performed with triplicate samples. (A) Representative histograms of activation markers MHC-II (HLA-DR), after 24h culture with positive gates shown. (B) Percentage of viable cells after 24h culture. (C) Percentage MHC-II (HLA-DR) positive cells gated on live cells. (D) Secreted IL-1β detected in 24h culture supernatants. (E) Secreted IL-8 detected in 24h culture supernatants. Significance tested by ANOVA with Dunnett’s post-test for all compared to control dmLT or LTA1 treatment (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). Bars at mean+SEM.